KalVista Pharmaceuticals (KALV) Presents Sebetralstat Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
September 6, 2024 6:30 AM EDTPatient perspectives shed additional light on the challenges of treating hereditary angioedema attacks with injectable on-demand therapies
New analyses of sebetralstat clinical trials bolster efficacy and safety profile
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented additional analyses of the efficacy and... More



